<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280110</url>
  </required_header>
  <id_info>
    <org_study_id>VPC1</org_study_id>
    <nct_id>NCT01280110</nct_id>
  </id_info>
  <brief_title>The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients</brief_title>
  <official_title>The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BAK is one of the most frequent preservatives in eye drops. BAK is a quaternary ammonium salt
      with surfactant qualities. It can be bacteriostatic or bactericidal depending on the
      concentrations used. It has been shown to be effective against most bacteria with a few
      exceptions, such as Pseudomonas aeruginosa, or picornaviruses. It as been widely used in
      eyedrops, nose sprays, hand and face washes, mouthwashes, spermicidal creams, and in various
      other cleaners, sanitizers, and disinfectants. BAK gained popularity when it was first
      introduced because it also enhances corneal penetration of some drugs by causing epithelial
      separation.

      It is present in several ophthalmic formulations, including most of the antiglaucoma
      medications. If used chronically, BAK has been found to cause ocular surface changes, such as
      dry eye and punctuate keratitis. BAK has also been suggested to promote a break in the blood
      aqueous barrier, which may lead to undesirable consequences, such as uveitis and cystoid
      macular edema. However, this information is controversial. The purpose of this study is to
      evaluate the consequences of BAK on the blood-retinal and blood-aqueous barriers of
      pseudophakic patients receiving BAK-preserved lubricating drops.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis behind the study is that BAK may lead to a break in the blood-retina
      barrier in pseudophakic eyes, leading to an increase in macular thickness, compared to a
      non-BAK containing solution. The secondary hypothesis is that solutions containing BAK will
      increase the permeability of the blood aqueous barrier compared to non-BAK solutions. If the
      hypotheses are confirmed, they may serve as a contraindication to the use of BAK-preserved
      drops in pseudophakic eyes requiring chronic use of medications.

      This is a prospective, randomized, examiner-masked, controlled study involving 44
      pseudophakic eyes of 44 patients. Patients receiving any other eyedrop, with a previous
      history of uveitis, posterior capsule rupture or any other ophthalmic surgery will be
      excluded. Patients will be randomized to the use of a BAK-preserved lubricating drop or to
      the use of a non-preserved lubricating drop q.i.d for one month. Effects on the blood aqueous
      barrier will be objectively measured with a laser flare meter (Kowa, Japan) at baseline, 15
      days and one month after inclusion. Patients will also have OCT images (Cirrus, Zeiss, USA)
      of the macula at the same time intervals to evaluate the possible effects on the blood-retina
      barrier. Macular thickness and the presence of cystoid macular edema will be evaluated at
      each time interval.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous Humor Flare</measure>
    <time_frame>Baseline, 15 days and 30 days.</time_frame>
    <description>Aqueous humor flare indicates the degree of a break in the blood-aqueous barrier. It is objectively measured with a Laser flare meter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular Thickness</measure>
    <time_frame>Baseline, 15 days and 30 days.</time_frame>
    <description>Macular thickness will be measured with an Optical coherence tomography (OCT). Measures 5% under the normal population according to the OCT software will be considered break in the blood-retina barrier.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Preserved (BAK 0.006%) lubricating drop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One group will receive preserved lubricating drops 4 times a day for 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative-free lubricating drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The second group will receive preservative-free lubricating drops 4 times a day for 1 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxypropylmethylcellulose</intervention_name>
    <description>22 patients will receive this lubricating drop 4 times a day for 1 month</description>
    <arm_group_label>Preserved (BAK 0.006%) lubricating drop</arm_group_label>
    <other_name>Retin Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboxymethylcellulose</intervention_name>
    <description>22 patients will receive this lubricating drop 4 times a day for 1 month.</description>
    <arm_group_label>Preservative-free lubricating drops</arm_group_label>
    <other_name>Optive UD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pseudophakic eyes that underwent cataract surgery at least 6 months before.

        Exclusion Criteria:

          -  Use of any eyedrop.

          -  Other conditions associated with a break in the blood-aqueous or blood retina barrier
             (ie diabetes, ARMD, vasculitis, uveitis)

          -  Previous history of cystoid macular edema.

          -  Previous ocular surgery other than cataract surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vital P Costa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University of Campinas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, University of Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Baudouin C, Labb√© A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010 Jul;29(4):312-34. doi: 10.1016/j.preteyeres.2010.03.001. Epub 2010 Mar 17.</citation>
    <PMID>20302969</PMID>
  </reference>
  <reference>
    <citation>Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004 Jul;23(5):490-6.</citation>
    <PMID>15220734</PMID>
  </reference>
  <reference>
    <citation>Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010 Nov;27(11):837-45. doi: 10.1007/s12325-010-0070-1. Epub 2010 Oct 7.</citation>
    <PMID>20931366</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <results_first_submitted>June 7, 2012</results_first_submitted>
  <results_first_submitted_qc>June 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2012</results_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Vital Paulino Costa</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>dry eye</keyword>
  <keyword>pseudophakia</keyword>
  <keyword>cornea</keyword>
  <keyword>lubricating drop</keyword>
  <keyword>BAK</keyword>
  <keyword>blood aqueous barrier</keyword>
  <keyword>blood-retina barrier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period started on March 2011 through December 2011 in the Department of Ophthalmology at the Hospital das Cl√≠nicas ‚Äì State University of Campinas.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Preserved (BAK 0.006%) Lubricating Drop</title>
          <description>One group will receive preserved lubricating drops 4 times a day for 1 month.</description>
        </group>
        <group group_id="P2">
          <title>Preservative-free Lubricating Drops</title>
          <description>The second group will receive preservative-free lubricating drops 4 times a day for 1 month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preserved (BAK 0.006%) Lubricating Drop</title>
          <description>One group will receive preserved lubricating drops 4 times a day for 1 month.</description>
        </group>
        <group group_id="B2">
          <title>Preservative-free Lubricating Drops</title>
          <description>The second group will receive preservative-free lubricating drops 4 times a day for 1 month.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="10.7"/>
                    <measurement group_id="B2" value="65.2" spread="12.2"/>
                    <measurement group_id="B3" value="67.1" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aqueous Humor Flare</title>
        <description>Aqueous humor flare indicates the degree of a break in the blood-aqueous barrier. It is objectively measured with a Laser flare meter.</description>
        <time_frame>Baseline, 15 days and 30 days.</time_frame>
        <population>Statiscal power of 80%.</population>
        <group_list>
          <group group_id="O1">
            <title>Preserved (BAK 0.006%) Lubricating Drop</title>
            <description>One group will receive preserved lubricating drops 4 times a day for 1 month. The flare will be evaluated with Laser Flare Cell Meter (Kowa, FM 500, Japan). The patients will have 3 evaluations (baseline, 15 days and 30 days). The baseline measure is done before the use of the eyedrops.</description>
          </group>
          <group group_id="O2">
            <title>Preservative-free Lubricating Drops</title>
            <description>he second group will receive preservative-free lubricating drops 4 times a day for 1 month. The flare will be evaluated with Laser Flare Cell Meter (Kowa, FM 500, Japan). The patients will have 3 evaluations (baseline, 15 days and 30 days). The baseline measure is done before the use of the eyedrops.</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Humor Flare</title>
          <description>Aqueous humor flare indicates the degree of a break in the blood-aqueous barrier. It is objectively measured with a Laser flare meter.</description>
          <population>Statiscal power of 80%.</population>
          <units>photons/msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="2.7"/>
                    <measurement group_id="O2" value="9.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="5.1"/>
                    <measurement group_id="O2" value="8.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="5.9"/>
                    <measurement group_id="O2" value="8.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Macular Thickness</title>
        <description>Macular thickness will be measured with an Optical coherence tomography (OCT). Measures 5% under the normal population according to the OCT software will be considered break in the blood-retina barrier.</description>
        <time_frame>Baseline, 15 days and 30 days.</time_frame>
        <population>Statiscal power of 80%</population>
        <group_list>
          <group group_id="O1">
            <title>Preserved (BAK 0.006%) Lubricating Drop</title>
            <description>One group will receive preserved lubricating drops 4 times a day for 1 month. The central macular thickness was obtained through Cirrus‚Ñ¢ HD-OCT (Zeiss). Mode 512x128 macular cube scan</description>
          </group>
          <group group_id="O2">
            <title>Preservative-free Lubricating Drops</title>
            <description>The second group will receive preservative-free lubricating drops 4 times a day for 1 month. The central macular thickness was obtained through Cirrus‚Ñ¢ HD-OCT (Zeiss). Mode 512x128 macular cube scan</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Thickness</title>
          <description>Macular thickness will be measured with an Optical coherence tomography (OCT). Measures 5% under the normal population according to the OCT software will be considered break in the blood-retina barrier.</description>
          <population>Statiscal power of 80%</population>
          <units>Œºm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258.5" spread="26.7"/>
                    <measurement group_id="O2" value="259.2" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.9" spread="24.2"/>
                    <measurement group_id="O2" value="256.4" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.9" spread="25.1"/>
                    <measurement group_id="O2" value="258.3" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Preserved (BAK 0.006%) Lubricating Drop</title>
          <description>One group will receive preserved lubricating drops 4 times a day for 1 month.</description>
        </group>
        <group group_id="E2">
          <title>Preservative-free Lubricating Drops</title>
          <description>The second group will receive preservative-free lubricating drops 4 times a day for 1 month.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vital Paulino Costa</name_or_title>
      <organization>Departamento de Oftalmologia - Universidade Estadual de Campinas - Campinas - Brazil</organization>
      <phone>55-19-35217396</phone>
      <email>vp.costa@uol.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

